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Ob+c,ivm. This stub was car&i eu, to drkrmiae the elect of 
ptirntr with chronic s,abk angbm. 
lhkgnwd. Myocmiiai iscbemia during awmal daily ilk, 
bo(b svmotomatic and awmdomadc. b&s been as.w&tfd wi,h 
1ai.G (beta-sdrwagic bkcking a&k in 65% ol petknta), 
patimb wltb chronic stabk angina 4th at kut tbm attacks or 
aogbm per web, mtb at kast kwr kcb.?mk epkadrr or r20 mtn 
01 ST sqntnt depressian in 48 b ul Hdtw monitorbtg, wclc 
randomized to mriw tmatmtnt with either 5 q #ddy olamkdip 
iw or piscrbn @:I nadomluthm). Tbr dole was ittcrwed to 
IO mg!day after 4 w&s. During wk 1 or tnrtmmt, 4&h 
nmbuktory ECC monitoring ms repeated. 
it is now appreciated lhal the activity of transient mywrdial 
iwhcmin in Cutients with chronic able angina is considenblv 
undrrestimaicd by the complaint of chat bin (i-3). iszhem~ 
activity can bc dwumcnted objectively during normal daiiy activ- 
itin using STsegment Hoitcr monitoring; the presence ofarymp 
tomatic myocardisl wbemin h% been related to increased mor- 
bidity and mortality (45). There is a pronounced circadian 
variation in irhemis chaoctetied by B peak incidence of epi- 
x&s in the wrly morning hours anda l&r incidence at night 
(6). This parallels the risk of ,tonlatal mywudiai infarction and 
sudden cardiac death (7,s). Incnxsingly, therefore. treatment 
regimes are being developed that target this 24-h patem of 
ischemia, both symptomatic and asymptomatic (9). Owed&y 
hcta-adrenergic blocking agents have been shown to be etctivc 
(i&i I). but dihydmkdine cakiumchannel bioeking agems 
with a short plasma half-life, such a? nifedipine capsules, have 
been disappointing because their p,mrmamkinetic and pharms 
mdynamic properties lead to uneven drug lwels throughout he 
day and to an unpredictable dose response in individual patients 
(9.11). Recently, a multicenter trial (12) using a deliq mtern 
for nifedipine that results in more stable plasma levels demon- 
strated benetit on symptomatic and silent ischemic episodes over 
24 h, especially when combined with a bata-blocker, indicating 
that sustained plasma levels of calcium channel blocker are 
associated with improved eficacy. 
Amlodipine is a novel dihydropyridme ;&mm channel 
blocker with a gradual ottsct of action and a long elirdination 
half-life (35 to 50 h). These favorable pbarmacokinetx and 
phawaccdynamic characteristin prcvide steady plasma 1weis 
with once-dai!y administration (13). Srverd clinical studies 
have f14.151 shown efficacv in patients wtb ancina and hvxr- 
tens& wiih a low incid&ce’of stde rffects.~f?~e Circ&n 
Anti-Ischemia Proerax~ in Eurooe (CX’E) xx desiened to 
test the elect of klodipine a&or cm&ted witi back- 
ground medical therapy on the circadian pattern of ischemlc 
episodes, angina attack rate and nitroglyce.in utilization in 
patients with chronic stable angina during nonm~l daily life. 
Methods 
Patients. Palientswere recruited at h3 sites in 10 European 
countriesbetween July IYSY and January IVY2 (see Appendix). 
Male outpatients between 35 and 80 ye&s of &w& &&d 
if they had stable angina prctoris with at Icast three atracks of 
angina per week with no change in symptoms for at least 
1 month and coronary artery disease on the basis of the 
presence of one or more of the following: 1. coronaty angiog- 
mphy demonstrating ~70% stenosis of one or more major 
coronary artety; 2. previous myocardial infarction 22 months 
before screening on the hasn of typical history, KG or 
enzymatic changes: 3. previous coronary artery bypass graft 
sorgmy or coronary mgioplasty. or both: 4. a positive exercise 
tolerance test within 12 months. 
Patients were excluded if they bad coqestive cardiac 
failure, uncontrolled arrhythmia o: hyperteosion, standing 
systolic bled pressure <Yll mm Hg heart rate <50 heatsimin. 
more than first-degree atrioventricular block or eni ECG 
feature that would interfere with interpretation of ST segment 
changes. All patients gave written consent. as approved by tbc 
institutional review boards fur the individual study sites. Suit- 
able patients, on the basis of these clinical criteria. then 
underwent 48-h ST segment Halter monitoring (see later). If 
they had four or more ischcmic episodes or 220 min of ST 
segment depression in 48 h, or both, they were randomized to 
the active phase of the study. P&en& were to bc maintained 
on stable doses of all concomitant cardiovascular medications 
(if any) throughout the study, and only those who had been 
receiving calcium channel blockers within I week before entry 
were excluded. Patients were instructed to take sublingual 
nitroglycerin for episodes of angina pectoris but not for 
prophylaxis, and open label nitroglycerin tablets were provided 
to ensure nonexpired medication. 
Shady design. This placebo-controlled study (Fig. I) COD 
sisted of an initial Z-week, single-blind placebo run-in period 
(phase 1) followed by randomized allocation to treatment in a 
29 amlodipine/placebn ratio. Patients then entered an S-week, 
double-blind treatment period (phase II). The study medica- 
tion was administered in blinded manner using a double- 
dummy design. with patients starting on 5 mg once daily of 
mther amlodipinc or placebo and increasing to IO mg after 
4 weeks of treatment. At the cod of the seventh week of phxse 
II, 4X-h ambuiatory ECG monitoring was rcpeatcd in an 
idenrical fashion to the initial evaluation. Throughout the 
rtudy, petients wxe instructed to record episodes of angina 
and wWnynl nitroglycerin tablet consumption and side cf- 
fects in a structured dimy. 
Ambulatory ECG manitating. Ambulatory ECG monitor- 
ing for ST segment analysis was performed using ACS 8500 
two-channel recorders with a modified V, lead for channel 1 
and V, o: 11 lead for channel 2. Each tape w= calibrated with 
:I 0.1.mV signal. At the screening via, recordings were made 
during seveo positional m~wuvers, and patients without arti- 
factitious ST segment shifts were then monitored for two 
consecutive 24-h periods (48 h). The tapes were analyzed at a 
central analysis facility (Medifacts) using a Marquette SW0 
Hoiter XP ~oalyzcr by three enperienced analysts for the 
number. magnitude and duration of irchemic episodes to a 15-s 
temporal resolution as well BE the presence of potentially 
serious arrhythmia. The investigator was notified of the results 
by telephone or facsimile, followed by a hard-copy report. If 
the patients fullil!ed the entry criteria for myocardial ischemic 
episodes, they were allouted a randomization number and 
entered into the active treatment phase. All recording of both 
oualifvine. and nonaualifvinc oatiems were then sent for 
dlindid &reading io thelsihemia Monitoring Laboratory a! 
Duke Univenitv. Durham. North Carolina. The final ceoorts . 
generated were used for determination of the study results. 
Analysis of the second 48-h period of ambulatory ECG mwt- 
itciinrwas &ormed in the same way, and data obtained were 
used br comparison with the b&line measurements. A
minimum of 18 h of technically satisfactory signal for ST 
segment analysis per 24-h record& was required ior inclusion 
in the final analysis. 
The ST segment was measured 80 ms after the J point; an 
episode was recorded if there was al mm of horizontal or 
downsloping ST depression for ~1 min. with rl-min separat- 
ing episode?. The duration of each episode was defined as the Table 1. Clinical Chararteristia of 315 Randomkd Patw~rs 
interval between the initial l-mm ST segment depression at the Amicdiplnc &c&o 
start of the episode and the rime at which the ST segment (” = Z02) (” = ,,a, 
depression became <l mm for >6O s at the end ci the epixde. 
Episodes of ST segment elevation were rare and thus not 
wan liStI, age br) 585 z 0.7 X6 t 0.8 
?.L,0.13-z6, 
included in any analysis of ST segnwnt changes. The use of a 
centralized labaratoty facility with a single physician overread 
nrovided mnsictencv for internretation of data. 
Statistical anal&s. The &wy efficacy measurements .&pm” 56% 56% 
from the ambulatory ECG data were 8s follows: 1) total Bavlinr BP (mm He) ,13,*3 L37,BJ 
frequency of episodes of ST segment depression; 2) total 
Barline HR (bcawnli”) 70 69 
duration of ST segment depression: 3) total integrated ST Nans olthcbavlinc rampanJonrberaren mlodipinc- and plrcehwcated 
ischsmic area (ST segmenr inregml); and 4) total peak ST paricnls rcaehed Iraiblical rignifrancs. AP = angna pecrorir: BP = blwd 
segment depression, that is, the maximal ST segment depres- 
prerrure: CABG = mronaiy ancry @a% gratr SY’&C’): HR = hean RrI: MI = 
sion wr &ode averaeed for each uatienl over 48 h. The 
myonrdia, n‘arerun: Fx.4 = ~rclllawxI t*n.l”mlnal coronary an~,loplar~. 
media” of ihe distributi& for each g&p was then evaluated. 
The ambulatory ECG data obtained during phase I saved as square tests with respect to the ranks and expected values, 
baseline. and the data at week 9 sewed as the final measure- were used for between-group differences in the change from 
ment. Baseline primary etlicacy meawrernents were assessed bwline. Analysis of diurnal distribution of &hernia was 
with analysis of variance models that included main effects performed wing repeated measures analysis of variance for 
(is.. treatment group and center) and interaction effects (i.e., the data in 3-h intervals: the models included treatment main 
treatment group by center). Although the center main effects effects and their interaction. The pattern of diUcrences in the 
were significant, no consistent putter” emerged actors vari- change from baseline was e@red using Duncan’s new mul- 
ablcs, and the interaction effects were not statistically siguifi- tiplc-range test. Patients’ self-assessments were obtained at 
cont. weeks 1 and 2 of phase I and weeks 6 ard 10 of phase 11. 
Secondary meawres of efficaq included angina attack rates Consistency during pretreatment (weeks I and 2) was tested 
and nitroglycerin tablet consumption obtained from the daily with paired t tests. Becaux none of these comparisons was 
diary data and the patients’ self-assessments of angina control significantly different (p > O.I), the values at the end of week 
and ability to perform usual physical activities derived from 2 were used as baseline for comparison with follow-up data. 
questionnaire data. The within-group daily diary changes cum- Analysis of covatiaucc models, with baseline as cmariate. were 
pared the weekly baseline (week 2) angina attack rate and used to evaluate the significance of between-group diffetenees 
nitroglycerin consumption with the data from the final week of in the change from baseline. Responder analyxs were per- 
treatment. Distribution-free stulistics were used to evaluate fornwd on angina diary data, patient self-aatwuena and the 
the data; within-group and between-group significance was investigator global assessn~ents of e&icy end toleration. 
determined with the Wilcoxon signed-rank and Wilcoxon These variables were dichotomized into improvement and no 
mnk-sum tests, respectively. improvement. The significance of the between-group re- 
Descriptive statistics, including mean values and standard spun&r rates was determined with Pearson chi-square tests. 
dcviaiions for normally distributed variables and median val- All adverse events were compiled regardless of cause. and 
“es and percentiles otherwise, were provided for baseline between-group differences were tested wilh Fisher exact tests. 
demographic and disease characteristics. Pearson chi.square Mean changes in bled pressure and heart rate were caku- 
tests were computed. and groups were examined for homoge- lated, and within-group changes were tested with paired t tests. 
neity at baseline. Between-group comparisons were made with Statistical analyses were performed with two-tailed tests using 
unpaired I tests. All continuous data were examined for statistical analysis software programs. and a” alpha level of 
nomxdity and formally rested with a Kolmogorov-Smirnuv 0.05 was assumed throughout the analysis. 
goodnessof-fit est. All 48-h Holler ECG dawwr-? emressed 
on a 24-h scale. 
The effect of treatment wus evaluated bv comnarison of 
changes from baseline in primary and se>o”da& efficacy 
measurements. Changes from baseline for continuous da!a 
were found not to be nornmlly distributed, but both square- 
toot and logarithmic transformations of the data fai!ed to 
provide satisfactory distribution. Nonparametric techniques 
were used for the forntnl data analysis, and medianswero wd 
to represent measures of central tendeney. Wilcoxon signed- 
rank tests were used for within-group change; and Wilcoxon 
rank-rum tests (kappa = 2 treatments), consisting of chi- 
Palieu data. Of 1,160 patients who were screened, 315 
were rondomixed (Table 1). Of these, 24 did not meet all 
protoeol requirements but were nevertheless included by the 
investigators (11 hod imporranr concomitant illnews; 11 had 
insticient &hernia during ambul;toty monitoring; 1 was 
fzmde: 1 was receiving a culcium channel blocker). 
Of the 315 patients entering the u&e treatment phase 
(phase II), 202 received amlodipine and 113 placebo. There 
were no signifxant differences in age, angina histoty, incidence 
p = 0.025 
of previous myocardial infarction or rerarcuhrization. heart 
rate or bload pressure between patients who received nmlo- 
dipine and placebo. The maioriw of the onfients in both croups 
w&e recei&tg more than a& conc&nitant cardio&c&r 
medication. including beta-blockers in 6% of nmlodipine- and 
61% of placebo-treated patients and aspirin in 5hc; of both 
treatment groups. 
One hundred ninety-one (95%) of amlodipine- and 100 
(88%) of placebo-treated patients completed the full eoursr of 
treatment. One paiient died in each group. and four (?.Il%) of 
amlodipine- and five (4.4%) of placebo-treated patients dis 
continued the studs because of adverse vents (see later). Mast 
other patients w&z dismntinued because o< pmtocoi viola- 
tions or elective operation. During phase II. 93% of amlodip- 
ine- and 89% of placebo-treated patients had their dose 
adjusted to 10 mgldoy as per protocol. 
Ambuleloty ECG mottitorlng. Of 315 patients randomwd 
to phase If, 250 patients (n = 167 for nmlodipine: n = R3 for 
placebo) were fully evalusble for ambulstory ECG analysis. 
The most eomnton problems were uninterpretable ECG dara 
or insufficient baseline ixhemia. Of those patients with evalu- 
able ECG data. 96% of amlodipinc- and IOIl% of placebo- 
treated patients received 10 mgiday. 
There was no significant difference between the baseline 
ixhemia characteri& in the 167 patients who received 
amlodipine and the 83 who received placebo. Before phase II. 
amlodi$ne-treated patients had P midinn number oi IO isch- 
emit episodes in 48 h versus 8 in placebo-treated patients. 
median isehemictimeaf60minvenus53 min. median peak ST 
segment depression of 1.84 verw LB!, mm and median 
ischemic ST segment intc.e,ral of 87 ~efsus 76 mm-min. r.espec- 
Episodes of transient myacardiol iscbemia were less frequent 
at the end of phase II in both amlopidine- and plwzba-treated 
patients. Tbc reduction in the frequency of ischemic ewms 
(median reduction 60% \x. X&S%, p = 0.025) and ST segment 
integral (mcdiw reduction 61.6% vs. 49.5S,, p = 0.042) ws 
significantly greater during amlodipine than placebo twnnent 
(Fig. 2). Amlodipine reduced the total duration of ST segmenr 
depression by 5660 mmpmedwith49.5% for placebo (p = 0.0%). 
Total peak ST segment depression was reduced by 14.3% dth 
amlodlpinr compared with 7.1% for placebo (p = 0.07). 
Circadiun variation. At initial monitoring, the wll known 
circadian pnttern in ischemic activity was present, with peaks in 
the morning and afternoon (Fig, 3). Amladipine significantly 
reduced ischemia throughout the day compared with placebo 
but did not abolish the underlying circadian variation; attenu- 
ated peaks in the morning and &muon were still present. 
Similar effects were seen for the duration of ST segment 
depression. ST integml nnd peak ST segment depression. 
Objective improvement in ischemia on ambulatory moni- 
toring was accompanied by improvement in subjective men- 
sums. During week 10, amlodipine-treated piltirnts esperi- 
cnccd a 7lG reduction in episodes of anginn pectoris (median 
attack rote 5 vs. Wweek) compared with 44% in placebo- 
treated patients (4 vs. 2Nweek. p = 0.0001) (Fig. 4). Seventy. 
nine pcrccnt of amlodipinc-treated patients, compared with 
59% of placebo-treated patients (p = O.OOal), reported fewer 
angina attacks during week IO. In ;tiddition. weekly nilro&v 
win consumotion with amlodioino was simificnntk reduced 
(by 67%. frbm median 2.9 t; 0.6 tablets) comp&d with 
placebo (by 22%. from median 2.5 to I.0 tablets) (p = O.OflO6). 
In patient self-assessment questionnaires. 75.3% ot 
amlodipinc-treated patients reported impmvement in their tively (p > 0.0s). 
ability t” perform usual physical activities compared with 
58.5% placebo-treated patients (p = lIW3). 
Heart rate and Mwd pressure. At?er 8 weeks of active 
tceatme”t. the patients who received amlodipine had a modest 
reduction in s&t& and diastolic blood pressures (133183 to 
126179 mm Hn vs. 137183 to W/83 mm He for n&e?“-heated 
patients). ‘&e was virtually no change ii hr:a:t rate in pither 
group throughout the 24 h (Fig. 5). 
Advent elf&. After randatition, 35 (179%)amkxlipine. 
treated and 15 (133%) placebo-treated pliientr repowd advers+ 
Figure 4. E&cl on angina frcqucnry. Amlcdipinc prrAduced a sig”iC 
icnntly greater reduction in media” angina attack rate than placebo 
(p = O.woI). 
Amkdlplm PlKIbo 
events (Table 2). Fobur (2%) amlodjpine-treated and frvr (4.4%) 
pbxeb+tre#ed patients dbmntinued treabnent, and fcur (2%) 
amlodipine-tread patients had a dase redtin fmm 10 to 
5 meNay. The mDSt freawnt cv~“ts we edema (5.4% with 
a&d&e. 1.8% ti &xbo), inaeaxd angina‘(24. with 
a”lkdipi”c, 35% with pixebo) and bca&cbe (25% with amlo- 
dipbx, 0.9% with placebo), “““e of the beiwe”gm”p mmpar- 
irons reached statiatkal sigaifmm. 0r.s @e”t in each g~“~p 
died (one had imulindaw&nt diabztw one had had disxmi- 
natedfareinoma). 
ThhmdyshawedthaIailewcEKedailyeakiumchaMel 
blocker, amlodipine, when added tobac!qrcu”d medica tbempy, 
redwed transient myrwdial Mania B patints with chnmic 
stable ““&a. The a”ti.i$cbeti e&t was &monstratcd by 
d$xtive measurement of ST segment changes during ambula- 
tay ECG monitoring and suppxted by imprcwnent in angina 
pstoris and nitmgtywrin tablet consumption. ‘fix bxeticial 
eti wra wsatmd over 24 h, and amlodipine was WI tolerated 
eve” at the higher dose wd (10 “I&. 
There has bee” great interest in measuring isehemic activity 
during nomA daily life in patients with coronary artery d&ax 
because it has become clear that ambulatory monitoring of ST 
segment changes can be used to dofumeni transient n&car- 
dial ixhemia and identify high risk subgroups of patients (16). 
Studies in patients with unstable angina (4), after myocardial 
infarction (17). chronic stable antia (5.18) and oerioheral 
vaxular dixase (1~) have shown &II thk ~r&“ce if n&xzx- 
dial ischemia defined in this way is a” independent marker of 
morbid events. I%rtbemwe. the pattern of ixhanic events 
over 24 h in patients with chronic stable angina has been linked 
t” that for major canliwaxular complications, such as my”- 
cardial infarction and sudden death (6-S). Attempts h.w 
therefore been made to dcvclop and test trcatmrnt rcgimcs for 
ischemis that target this pattei:, :tr?~~nout rhc 24 h. 
Medical treatment of myocardial isehemin. Once-dady 
beta-blacken have proved effective in reducing wchemic xfiv- 
ity over 24 h but characteristically exert their greatest effect on 
ischemic episodes that are preceded by 80 increw in heart 
rate (28). In the remainder, which are not prcccded by 
evidence of increased myocardial oxygen demand. dihydropy- 
ridine calcium channel blacken have been shown to be ebc- 
tive (20). However, the data for the tint-generation agemD. 
such as nifedioine. have been confiictinr! (21.22). When tested “. 
over 24 h, the effect of nifcdipinc cups&s on the circadian 
pattern of ischemia has been disappointins. dnd this YCT)I likely 
relates to its rapid absorption and short p!asma half-life (Y). 
These pharmacokinetic characteristics result in varinblc 
plasma lcvcls of the drug throughout the day. with r&s 
tachynrdia and whodilator side eiiects at peak Bvels as uell ilb 
rubthelapeutic lrvels at other times. In contmst, rficxy has 
been demonstratedwhen the drug is given with n novel delivcly 
systea (gastrointestinal thempeutic system [GITS]) that re- 
suits in more even plasma levels (12). Amlodipine is a rcccndy 
developed dihydropyridine calcium channel blocker that has a 
distinctive ohamncokinelic and ohammcodvnamic orofilc. in- 
eluding gradual onset, intrinsicilliy long do&ion of &lion and 
a olasmn elimination half-ID of 35 to 50 h. When riven once 
a day it prcduces very stable plasma levels over 24 i and thus 
avoids the need for a slow-rcluw preparation or a dclivcry 
3ystem (13). This bns a number of advanteges. parricularly 
when dosing intervals are variable, as is often the case in 
clinical practice (23). In this study, amlodipine was given in 
addition to background medical therapy. which included beta- 
blockers in -65% of patients. Tbc observed benefit from 
amlodipine is mnsistent with the theoretic advantages of this 
comb&lion of dihydropyridinc alcium chunnel blockers md 
beta-blockers (20) and with previous observations using ambu- 
latory measures of ischcmia (12.24). The findings of this large 
trial support reports of smaller studies (25) showing improve- 
ment in exercise testing measuresof &hernia with amlodipine. 
b 
A miqor advantage of amludipinc o\‘er short-actmg dihy. 
dropyl~dincs. such ds nifedipine capsules, is the lack of 
rcfln tachycardlia. There wn no significant increase in heart 
raw tound at any time of tbc day, and this presumably is one 
fxror canlrihuting to both lbc cikxy noted over the whole 
24 h and the low incidence of adverse etTects with andodip- 
inr. In addition. there were no adverse electrophyciologic 
eRcts noted when the drug was used ;alone or in combina- 
tion with a hetahlocker. 
.tibulntoly ECG monitoring. ST segment changes in am- 
bulatory ECG monitoring was the primaty end point of the 
study (26). To maximize specificity as a marker of ischemin. we 
conlincd inclusion to men in whom the reliabilitvof this ECG 
stgnnl is greatest. Because there has been con~derable vnri- 
ability in reporting of ambulatory ECG ST segment findings, 
we used ;I single, experienced core laboratory for analysis. with 
review of all reoorts bv one physician. In this trial. patientswith 
sufficient isch&a w&c en&d while co&& thcw usual 
medical therapy (if any) to which naive amlodipinc or placeho 
was added in a double-blind fashion. Approximately 6X of 
the patients were receiving beta-block& nnd this, rogerher 
with the ?: I randomization. resulted in too small a suberouo of _ . 
patients receiving active omlodipine or placebo monotherapy 
for sepsmte analysis. Entry into the study required the pres- 
ence of both angina and at least four episodes of amhulatoty 
ischemia. As :I result of these rigorous criteria. patients were in 
an a&c phase of their disrare at the start of the study. This 
may at least partially explain ihc considernhle improvement in 
objective snd subjective measures of ischemia lso sew in the 
patients treated with placebo, as a result of “regression to the 
mean.” Nevertheless, despite the placebo groups improve- 
ment, the patients treated ai!h acriyc medication showed 
significantly more benefit in horh ambulatory ECG ischemia 
and angin; pectoris. The recruitment rate of 30% achieved in 
this study is Ihigher than that of previously published ctudies 
using ambulatory ECG monitoring inclusion criteria (16% of 
409 patients screened for the Regionally Organized Cardiac 
Key European Trial (RCXKET) 1271 and 18% in the Nifedip 
ine GITS Circadian Anti-lwhemia Program (N-CAP) studies 
M. 
Clinical implkatlons. The true “once-daily” calcium 
chsnncl blocker amlodipine provides effeclive treatment of 
transient myocardial ischemi.: over 24 h in palicnts 
with chronic stable sngina. particularly when combined 
with a beta-blocker. In view of the known high incidence of 
ischemia in the enrly morning hours and Ihe higher risk of 
serious cardiovasculsr events during this period, the long 
duration of &cl of amlodipine with a low incidence of side 
effects may provide important clinical benefit. The availabil. 
ity of cUecrivc medical regimes lhat target ischemia over 
the whole 24 h will enable prospective clinical trials to 
test whether this approach 16 treatment of patients with 
chronic stable angina will result in improved morbidity and 
mortality (2X). 
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